240 related articles for article (PubMed ID: 32026322)
1. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH
Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid).
Kashani B; Zandi Z; Bashash D; Zaghal A; Momeny M; Poursani EM; Pourbagheri-Sigaroodi A; Mousavi SA; Ghaffari SH
Cancer Chemother Pharmacol; 2020 Jan; 85(1):47-59. PubMed ID: 31786654
[TBL] [Abstract][Full Text] [Related]
3. The anticancer effect of the TLR4 inhibition using TAK-242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer.
Zandi Z; Kashani B; Bashash D; Poursani EM; Mousavi SA; Chahardoli B; Ghaffari SH
J Cell Biochem; 2020 Feb; 121(2):1623-1634. PubMed ID: 31535397
[TBL] [Abstract][Full Text] [Related]
4. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
Zandi Z; Kashani B; Poursani EM; Bashash D; Kabuli M; Momeny M; Mousavi-Pak SH; Sheikhsaran F; Alimoghaddam K; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2019 Jun; 853():256-263. PubMed ID: 30930249
[TBL] [Abstract][Full Text] [Related]
5. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
6. Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling.
Sun T; Liu Y; Li M; Yu H; Piao H
Mol Cell Probes; 2020 Oct; 53():101602. PubMed ID: 32447047
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation.
Baakhlagh S; Kashani B; Zandi Z; Bashash D; Moradkhani M; Nasrollahzadeh A; Yaghmaei M; Mousavi SA; Ghaffari SH
Int Immunopharmacol; 2021 Jan; 90():107202. PubMed ID: 33278749
[TBL] [Abstract][Full Text] [Related]
8. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
Sootichote R; Thuwajit P; Singsuksawat E; Warnnissorn M; Yenchitsomanus PT; Ithimakin S; Chantharasamee J; Thuwajit C
BMC Cancer; 2018 Feb; 18(1):231. PubMed ID: 29486738
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
[No Abstract] [Full Text] [Related]
10. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Chiba Y; Sato S; Itamochi H; Yoshino N; Fukagawa D; Kawamura H; Suga Y; Kojima-Chiba A; Muraki Y; Sugai T; Sugiyama T
Int J Gynecol Cancer; 2017 Oct; 27(8):1666-1674. PubMed ID: 28786875
[TBL] [Abstract][Full Text] [Related]
12. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.
Matsunaga N; Tsuchimori N; Matsumoto T; Ii M
Mol Pharmacol; 2011 Jan; 79(1):34-41. PubMed ID: 20881006
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
14. TLR4 is a novel determinant of the response to paclitaxel in breast cancer.
Rajput S; Volk-Draper LD; Ran S
Mol Cancer Ther; 2013 Aug; 12(8):1676-87. PubMed ID: 23720768
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
Zhang R; Yang X; Roque DM; Li C; Lin J
PLoS One; 2021; 16(4):e0240145. PubMed ID: 33909625
[TBL] [Abstract][Full Text] [Related]
16. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract][Full Text] [Related]
17. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
18. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
Seino M; Okada M; Sakaki H; Takeda H; Watarai H; Suzuki S; Seino S; Kuramoto K; Ohta T; Nagase S; Kurachi H; Kitanaka C
Oncol Rep; 2016 Jan; 35(1):593-601. PubMed ID: 26534836
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
[TBL] [Abstract][Full Text] [Related]
20. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
